フロントテンポラル認知症の併発性発作は 何を示しているのでしょう?
Syeda Amrah Hashmi1, Mark Quigg1, Anelyssa D'Abreu1
1Department of Neurology, University of Virginia School of Medicine, Charlottesville, VA, United States.
Epilepsy research
|August 20, 2025
まとめ
フロントテンポラル認知症 (FTD) の患者では,併発性発作,しばしば行動型FTD (bvFTD) が7. 6%の罹患率を示しています. トラウマ性脳損傷は主要なリスク因子であり,ほとんどの患者は抗発作薬 (ASM) で発作をコントロールできます.
科学分野:
- 神経科学
- 神経科学
- 臨床医学
背景:
- 併発性発作は前頭葉認知症 (FTD) の患者の2〜11%に影響する.
- 発作性FTDにおけるリスク要因,臨床的特徴,発作のアウトカムについては十分に研究されていない.
研究 の 目的:
- FTD患者における発作の流行,危険因子,臨床的特徴,アウトカムを調査する.
- 発作に関連した特定のFTDサブタイプと併発症を特定する.
主な方法:
- 2011年5月1日から2024年4月30日までの間に診断されたFTD患者317人の遡及分析.
- 患者はbvFTD,svPPA,またはnfPPAに分類され,FTDと発作 (FTD+SZ) または無 (FTD-SZ) と分類された.
- 人口統計,併発症,認知症,発作の特徴に関するデータは,電子医療記録から抽出され,統計分析にはChi- squared,Fisher Exact,tテストが含まれていた.
主要な成果:
- FTD患者の7. 6% (24/317) が発作 (FTD+SZ) を経験した.
- トラウマ性脳損傷 (TBI) は有意なリスク因子 (p < 0. 001) であり,FTD+SZでは不安がより一般的であった (p=0. 0392).
- 行動変異性FTD (bvFTD) は最も一般的なサブタイプであり,焦点発作,特に側頭葉の (TLE) が優勢であった. 87. 5% は抗発作薬 (ASM) で発作制御を達成しました.
結論:
- この研究は,FTDにおける発作の7. 6%の有病率を特定し,主にbvFTDで発作が集中発作 (TLE) で特徴づけられた.
- 不安とTBIは発作と関連しており,ASMでは一般的にうまく制御された.
- FTDの発作患者は死亡時に年齢がより高かったため,診断と治療に関するさらなる研究が必要であることが明らかになった.
さらに関連する動画
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.8K
12:09Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy
Published on: August 5, 2014
18.1K
関連する概念動画
01:13Seizures: Classification
586
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
586
01:24Epilepsy and Seizures: Overview
277
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
277
01:30Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:15Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703